Biosig Technologies, INC

Streamex Corp. announced the resignation of board member Shawn Matthews, effective July 29, 2026, with the company exploring options to fill the vacancy.

Streamex Corp. has dismissed CBIZ CPAs P.C. as its independent auditor and appointed EisnerAmper LLP as its successor.

Streamex Corp. has partnered with Orca to launch a 24/7 decentralized secondary liquidity infrastructure for its gold-backed GLDY token on the Solana blockchain.

Streamex Corp. announced the appointment of Kori Handy, a former lead product designer from Microsoft and PayPal, as its new Vice President of Product and Design.

Streamex Corp. announces executive employment agreement amendments and a new director appointment, detailing compensation, equity awards, and severance.

Streamex Corp. hosted a webcast on April 8, 2026, to discuss its 2025 financial results and provide corporate updates.

Streamex Corp. reports Q1 2026 financial results, highlighting the successful repayment of convertible debt and the expansion of its digital asset infrastructure.

Streamex Corp. reported a significantly wider net loss in Q3 2025, driven by its strategic acquisition of Streamex Exchange and a pivot towards digital commodity trading and blockchain technology.

BioSig Technologies reports a significant increase in net loss and working capital deficit for Q2 2025, driven by the Streamex acquisition and related expenses, while securing substantial new financing.

BioSig Technologies reports a net loss for Q1 2025 but regains compliance with Nasdaq listing requirements.

BioSig Technologies reports its Q3 2024 results, highlighting a significant reduction in operating expenses, a gain from debt settlement, and the reinstatement of its Nasdaq listing, while also noting ongoing financial challenges and internal control weaknesses.

BioSig Technologies reports a net loss of $7.455 million for the six months ended June 30, 2024, while navigating delisting from Nasdaq and significant operational changes.

Streamex Corp. (formerly BioSig Technologies, Inc.) completed a strategic pivot to tokenized asset finance in 2025, reporting a significant net loss driven by non-cash derivative liabilities, while strengthening its liquidity post-year-end.

BioSig Technologies reports its annual results on Form 10-K, highlighting ongoing efforts to regain Nasdaq compliance amidst financial challenges and a potential delisting.

BioSig Technologies is facing potential delisting from the Nasdaq Capital Market due to non-compliance with listing rules, workforce reductions, and resignations of key personnel.

Streamex Corp. Director Shawn Matthews acquired 100,000 shares of common stock through a restricted stock award.

Streamex Corp. Director Kevin Roy Gopaul acquired 100,000 shares of common stock through a restricted stock award.

Morgan Lee Lekstrom, Director and Officer of Streamex Corp., reported the acquisition of 50,000 common shares through two transactions on June 12, 2026.

Chief Investment Officer Mitchell Young Williams sold 23,810 shares of Streamex Corp. to satisfy tax withholding requirements following RSU vesting.

Interim Executive Chairman Morgan Lekstrom files an amendment to correct beneficial ownership reporting for Streamex Corp.

Interim Executive Chairman Morgan Lekstrom filed an amendment to correct previously reported share acquisition and ownership totals.

Streamex Corp. is calling its 2025 Annual Meeting to elect directors, approve executive compensation, and significantly increase its long-term incentive plan shares by over 22 million.

Streamex Corp. announced Nasdaq approval for continued listing and will reconvene a special shareholder meeting on November 4, 2025, to vote on an acquisition proposal.

BioSig Technologies' stockholders approved significant increases in authorized shares, a long-term incentive plan amendment, and a classified board, while adjourning a vote on shares for the Streamex acquisition.

BioSig Technologies announced the adjournment of a key shareholder vote for its Streamex merger due to pending Nasdaq approval, though the merger itself and company operations remain unaffected.

BioSig Technologies, Inc. announced an amendment to its proxy statement, adjourning the vote on the Streamex acquisition proposal to a later date pending Nasdaq approval.

BioSig Technologies, Inc. has withdrawn the proposal for stockholder approval of share issuance related to its Streamex acquisition from the upcoming Special Meeting.

BioSig Technologies files an amendment to its Form S-1 registration statement for the resale of up to 1,680,631 shares of common stock issuable upon the exercise of outstanding warrants.

BioSig Technologies is registering for resale up to 1,680,631 shares of its common stock by selling stockholders, which are issuable upon the exercise of outstanding warrants.

Karl Henry Michael McPhie, co-founder of Streamex, becomes CEO of Streamex Corp. and discloses beneficial ownership of 14.2% of common stock following a share exchange.

Morgan Lee Lekstrom, Chairman of Streamex Corp., has disclosed a 13.99% beneficial ownership stake in the company following a share exchange related to the acquisition of Streamex.

Avanico Limited and Frank Giustra have filed an amended Schedule 13G, correcting previously reported beneficial ownership in Streamex Corp. to 12.02%.

Avanico Limited and Frank Giustra have disclosed a 12.13% beneficial ownership stake in BioSig Technologies, Inc., primarily through exchangeable shares contingent on future stockholder approval.